The information gathered during the discover process, as well as user flows, allows you to build wireframes and get a feel for how your end product will look.Workshops are then used to validate your solution and create a development plan.Tokyo, Japan/Little Chesterford, UK & Chippenham, UK –17 October 2005: Arakis Ltd.
G&T is an independent construction and property consultancy working across all sectors of the built environment.
NVA237 is being developed and commercialised by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol (QAB149), under the terms of the agreement signed in April 2005.
The study is a randomised, double-blind, multi-centre, placebo-controlled trial designed to evaluate the efficacy, safety and dose response of NVA237 in patients diagnosed with COPD over a four week period.
In addition to NVA237, Arakis has three other products in clinical development: AD 452 for rheumatoid arthritis (RA) which has completed Phase IIa trials, and AD 337 for fibromyalgia syndrome and AD 923 for cancer breakthrough pain (CBP) which are both in Phase I.
In addition, there is a preclinical pipeline of other opportunities, two exploratory developments and a number of research projects.